Effect of anti-COVID-19 drugs on patients with cancer

被引:1
|
作者
Huang, Weicai [1 ]
Liu, Wenyu [1 ]
Yu, Tingting [1 ]
Zhang, Zhaoyang [1 ]
Zhai, Lingyun [2 ]
Huang, Panpan [1 ]
Lu, Yao [1 ]
机构
[1] Gannan Med Univ, Sch Basic Med, Ganzhou 341000, Jiangxi, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Gynecol Dept, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China
关键词
Cancer; COVID-19; Drugs; Tumor progression; GAMMA INHIBITS GROWTH; INTERFERON-GAMMA; LUNG-CANCER; COVID-19; SEVERITY; CARCINOMA-CELLS; RISK-FACTORS; IFN-GAMMA; T-CELLS; RIBAVIRIN; TOCILIZUMAB;
D O I
10.1016/j.ejmech.2024.116214
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The clinical treatment of patients with cancer who are also diagnosed with coronavirus disease (COVID-19) has been a challenging issue since the outbreak of COVID-19. Therefore, it is crucial to understand the effects of commonly used drugs for treating COVID-19 in patients with cancer. Hence, this review aims to provide a reference for the clinical treatment of patients with cancer to minimize the losses caused by the COVID-19 pandemic. In this study, we also focused on the relationship between COVID-19, commonly used drugs for treating COVID-19, and cancer. We specifically investigated the effect of these drugs on tumor cell proliferation, migration, invasion, and apoptosis. The potential mechanisms of action of these drugs were discussed and evaluated. We found that most of these drugs showed inhibitory effects on tumors, and only in a few cases had cancer-promoting effects. Furthermore, inappropriate usage of these drugs may lead to irreversible kidney and heart damage. Finally, we have clarified the use of different drugs, which can provide useful guidance for the clinical treatment of cancer patients diagnosed with COVID-19.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Research and development of Chinese anti-COVID-19 drugs
    Ji, Xiwei
    Meng, Xiangrui
    Zhu, Xiao
    He, Qingfeng
    Cui, Yimin
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (12) : 4271 - 4286
  • [2] Research and development of Chinese anti-COVID-19 drugs
    Xiwei Ji
    Xiangrui Meng
    Xiao Zhu
    Qingfeng He
    Yimin Cui
    ActaPharmaceuticaSinicaB, 2022, 12 (12) : 4271 - 4286
  • [3] Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
    Liu, Dongling
    Zeng, Xiang
    Ding, Zufeng
    Lv, Fenghua
    Mehta, Jawahar L.
    Wang, Xianwei
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [4] Progress in the Research and Development of Anti-COVID-19 Drugs
    Huang, Lianzhou
    Chen, Yuanqiu
    Xiao, Ji
    Luo, Weisheng
    Li, Feng
    Wang, Yuan
    Wang, Yiliang
    Wang, Yifei
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [5] CNS penetration of potential anti-COVID-19 drugs
    Peter J. Richardson
    Silvia Ottaviani
    Alessandro Prelle
    Justin Stebbing
    Giacomo Casalini
    Mario Corbellino
    Journal of Neurology, 2020, 267 : 1880 - 1882
  • [6] CNS penetration of potential anti-COVID-19 drugs
    Richardson, Peter J.
    Ottaviani, Silvia
    Prelle, Alessandro
    Stebbing, Justin
    Casalini, Giacomo
    Corbellino, Mario
    JOURNAL OF NEUROLOGY, 2020, 267 (07) : 1880 - 1882
  • [7] Anti-COVID-19 drugs, COVID-19 and anesthetics - The challenge for anesthesiologists
    Garg, Rakesh
    Yadav, Pratishtha
    JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 : 140 - 141
  • [8] A Narrative Review of the Safety of Anti-COVID-19 Nutraceuticals for Patients with Cancer
    Bader-Larsen, Karlen Stade
    Larson, Elisabeth Anne
    Dalamaga, Maria
    Magkos, Faidon
    CANCERS, 2021, 13 (23)
  • [9] Anti-COVID-19 drugs, COVID-19 and anesthetics-The challenge for anesthesiologists
    Garg, Rakesh
    Yadav, Pratishtha
    JOURNAL OF ANAESTHESIOLOGY CLINICAL PHARMACOLOGY, 2022, 38 (05) : 140 - 141
  • [10] Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs
    Nicholson, Martin W.
    Huang, Ching-Ying
    Wang, Jyun-Yuan
    Ting, Chien-Yu
    Cheng, Yu-Che
    Chan, Darien Z. H.
    Lee, Yi-Chan
    Hsu, Ching-Chuan
    Hsu, Yu-Hung
    Chang, Cindy M. C.
    Hsieh, Marvin L.
    Cheng, Yuan-Yuan
    Lin, Yi-Ling
    Chen, Chien-Hsiun
    Wu, Ying-Ta
    Hacker, Timothy A.
    Wu, Joseph C.
    Kamp, Timothy J.
    Hsieh, Patrick C. H.
    PHARMACEUTICALS, 2022, 15 (06)